The FDA has granted accelerated approval to an immunotherapy to treat certain adult patients with endometrial cancer that tests positive for a specific biomarker. The U.S. Food and Drug Administration (FDA) has granted accelerated...
The FDA has approved an immunotherapeutic in combination with chemotherapy to treat certain patients with gastric cancer, gastroesophageal junction cancer, and a common form of esophageal cancer. The U.S. Food and Drug Administration (FDA)...
The FDA granted accelerated approval to the targeted therapeutic sacituzumab govitecan to treat certain patients with the most common form of bladder cancer. The U.S. Food and Drug Administration (FDA) recently granted accelerated approval...
The FDA approved the first CAR T-cell therapy to treat certain adult patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved idecabtagene vicleucel (Abecma) to treat adult patients with relapsed...
the immunotherapeutic pembrolizumab in combination with chemotherapy WAS APPROVED to treat certain adult patients with esophageal cancer. The U.S. Food and Drug Administration (FDA) recently approved the immune checkpoint inhibitor pembrolizumab (Keytruda) in combination...
The FDA approved the molecularly targeted therapeutic tivozanib to treat certain adult patients with the most common type of kidney cancer. The U.S. Food and Drug Administration (FDA) has approved tivozanib (Fotivda) to treat...
The FDA granted accelerated approval to a CAR T-cell therapy for certain adult patients with follicular lymphoma, a common type of non-Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) granted accelerated approval to...
The FDA has approved an immune checkpoint inhibitor – a type of cancer immunotherapy – as a first-line therapeutic for certain patients with non-small cell lung cancer.
The FDA approved the immune checkpoint inhibitor, cemiplimab-rwlc, for certain patients with locally advanced or metastatic basal cell carcinoma
The FDA approved a CAR T-cell therapy – a class of cancer immunotherapy – to treat certain patients with large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More